NEW YORK (GenomeWeb News) – Response Genetics has launched a public offering of nearly 4.5 million shares of its common stock at $1.20 per share.

The Los Angeles-based molecular diagnostics firm said that it expects to raise about $4.8 million in net proceeds, which it will use for working capital and general corporate purposes. It could realize additional proceeds if underwriters of the offering exercise their over-allotment option of 669,666 shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."

The US Food and Drug Administration has approved four molecularly targeted drugs this month, suggesting that personalized medicine has "turned a corner."

In Science this week: caution urged in use of gene drives, and more.